4//SEC Filing
VERTEX PHARMACEUTICALS INC / MA 4
Accession 0001209191-14-073398
$VRTXCIK 0000875320operating
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 4:25 PM ET
Size
13.0 KB
Accession
0001209191-14-073398
Insider Transaction Report
Form 4
Connolly Thomas
SVP, Human Resources
Transactions
- Sale
Common Stock
2014-12-04$120.62/sh−100$12,062→ 34,895 total - Exercise/Conversion
Stock Option (right to buy)
2014-12-04−937→ 6,563 totalExercise: $53.74Exp: 2022-09-03→ Common Stock (937 underlying) - Exercise/Conversion
Common Stock
2014-12-04$53.74/sh+937$50,354→ 35,832 total - Sale
Common Stock
2014-12-04$118.40/sh−500$59,200→ 35,332 total - Sale
Common Stock
2014-12-04$119.36/sh−337$40,224→ 34,995 total
Holdings
- 150(indirect: By 401(k))
Common Stock
Footnotes (5)
- [F1]Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.
- [F2]Open market sales reported on this line occurred at a weighted average price of $118.40 (range $117.92 to $118.86).
- [F3]Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- [F4]Open market sales reported on this line occurred at a weighted average price of $119.36 (range $118.95 to $119.82).
- [F5]The option vests in 16 quarterly installments from 09/04/2012.
Documents
Issuer
VERTEX PHARMACEUTICALS INC / MA
CIK 0000875320
Entity typeoperating
IncorporatedMA
Related Parties
1- filerCIK 0000875320
Filing Metadata
- Form type
- 4
- Filed
- Dec 4, 7:00 PM ET
- Accepted
- Dec 5, 4:25 PM ET
- Size
- 13.0 KB